CD19 and congenital rubella syndrome: Blinatumomab, a monoclonal antibody, targeting CD19 antigen and anti-CD19 CAR-T cells are also approved for R/R ALL children with rare oral effects [55] They induce an immune response which can evolve to cytokine release syndrome (CRS) and neurological toxicity.